News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Karolinska Development AB: Pharmanest Initiates Phase II Study of SHACT


6/12/2012 10:23:50 AM

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Today, Pharmanest AB announced that the first patient has been dosed in a randomized Phase II study of SHACT, a product developed for pain relief associated with intrauterine device (IUD) insertion. Karolinska Development AB (STO:KDEV) owns 58.9 percent of Pharmanest.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES